| Date:2023-3-1                                                                                          |
|--------------------------------------------------------------------------------------------------------|
| Your Name: Yufeng Ba                                                                                   |
| Manuscript Title: Case report: targeted sequencing improves the diagnosis of multiple synchronous lung |
| <u>cancers</u>                                                                                         |
| Manuscript number (if known):                                                                          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                          | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 1 | All consent for the consent                              |                                                                                                                                           | planning of the work                                                                |
| 1 | All support for the present                              | None                                                                                                                                      |                                                                                     |
|   | manuscript (e.g., funding, provision of study materials, |                                                                                                                                           |                                                                                     |
|   | medical writing, article                                 |                                                                                                                                           |                                                                                     |
|   | processing charges, etc.)                                |                                                                                                                                           |                                                                                     |
|   | No time limit for this item.                             |                                                                                                                                           |                                                                                     |
|   |                                                          |                                                                                                                                           |                                                                                     |
|   |                                                          |                                                                                                                                           |                                                                                     |
|   |                                                          | Time frame: past                                                                                                                          | 36 months                                                                           |
| 2 | Grants or contracts from                                 | None                                                                                                                                      |                                                                                     |
|   | any entity (if not indicated                             |                                                                                                                                           |                                                                                     |
|   | in item #1 above).                                       |                                                                                                                                           |                                                                                     |
| 3 | Royalties or licenses                                    | None                                                                                                                                      |                                                                                     |
|   |                                                          |                                                                                                                                           |                                                                                     |
|   |                                                          |                                                                                                                                           |                                                                                     |
| 4 | Consulting fees                                          | None                                                                                                                                      |                                                                                     |
|   |                                                          |                                                                                                                                           |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 44 | group, paid or unpaid                        | Al   |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                          |  |  |  |  |
|--------------------------------------------------------------------------------------------------------|--|--|--|--|
| Your Name: Haomiao Li                                                                                  |  |  |  |  |
| Manuscript Title: Case report: targeted sequencing improves the diagnosis of multiple synchronous lung |  |  |  |  |
| <u>cancers</u>                                                                                         |  |  |  |  |
| Manuscript number (if known):                                                                          |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                          |
|--------------------------------------------------------------------------------------------------------|
| Your Name: Jianping Zhu                                                                                |
| Manuscript Title: Case report: targeted sequencing improves the diagnosis of multiple synchronous lung |
| <u>cancers</u>                                                                                         |
| Manuscript number (if known):                                                                          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                          |  |  |  |  |
|--------------------------------------------------------------------------------------------------------|--|--|--|--|
| Your Name: Haoran Wang                                                                                 |  |  |  |  |
| Manuscript Title: Case report: targeted sequencing improves the diagnosis of multiple synchronous lung |  |  |  |  |
| <u>cancers</u>                                                                                         |  |  |  |  |
| Manuscript number (if known):                                                                          |  |  |  |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                                 |
|---------------------------------------------------------------------------------------------------------------|
| Your Name:Hongwei Lv                                                                                          |
| Manuscript Title: <u>Case report: targeted sequencing improves the diagnosis of multiple synchronous lung</u> |
| <u>cancers</u>                                                                                                |
| Manuscript number (if known):                                                                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                                 |
|---------------------------------------------------------------------------------------------------------------|
| Your Name:Chongqing Guo                                                                                       |
| Manuscript Title: <u>Case report: targeted sequencing improves the diagnosis of multiple synchronous lung</u> |
| <u>cancers</u>                                                                                                |
| Manuscript number (if known):                                                                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of interest to declare |  |  |  |
|------------------------------------------------------|--|--|--|
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |
|                                                      |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                                 |
|---------------------------------------------------------------------------------------------------------------|
| Your Name: Rui Sun                                                                                            |
| Manuscript Title: <u>Case report: targeted sequencing improves the diagnosis of multiple synchronous lung</u> |
| <u>cancers</u>                                                                                                |
| Manuscript number (if known):                                                                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of | of interest to declare |  |
|----------------------------------|------------------------|--|
|                                  |                        |  |
|                                  |                        |  |
|                                  |                        |  |
|                                  |                        |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                                 |
|---------------------------------------------------------------------------------------------------------------|
| Your Name: Jiawen Zheng                                                                                       |
| Manuscript Title: <u>Case report: targeted sequencing improves the diagnosis of multiple synchronous lung</u> |
| <u>cancers</u>                                                                                                |
| Manuscript number (if known):                                                                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                     | None |  |
|----|----------------------------------------------|------|--|
|    | lectures, presentations,                     |      |  |
|    | speakers bureaus,                            |      |  |
|    | manuscript writing or                        |      |  |
|    | educational events                           |      |  |
| 6  | Payment for expert                           | None |  |
|    | testimony                                    |      |  |
| _  |                                              |      |  |
| 7  | Support for attending meetings and/or travel | None |  |
|    |                                              |      |  |
|    |                                              |      |  |
| 8  | Patents planned, issued or                   | None |  |
|    | pending                                      |      |  |
|    |                                              |      |  |
| 9  | Participation on a Data                      | None |  |
|    | Safety Monitoring Board or                   |      |  |
|    | Advisory Board                               |      |  |
| 10 | Leadership or fiduciary role                 | None |  |
|    | in other board, society,                     |      |  |
|    | committee or advocacy                        |      |  |
| 11 | group, paid or unpaid                        | Mana |  |
| 11 | Stock or stock options                       | None |  |
|    |                                              |      |  |
| 12 | Receipt of equipment,                        | None |  |
| 12 | materials, drugs, medical                    | None |  |
|    | writing, gifts or other                      |      |  |
|    | services                                     |      |  |
| 13 | Other financial or non-                      | None |  |
|    | financial interests                          |      |  |
|    |                                              |      |  |
|    |                                              |      |  |

| The authors have no conflicts of | of interest to declare |  |
|----------------------------------|------------------------|--|
|                                  |                        |  |
|                                  |                        |  |
|                                  |                        |  |
|                                  |                        |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                          |
|--------------------------------------------------------------------------------------------------------|
| Your Name: Lin Meng                                                                                    |
| Manuscript Title: Case report: targeted sequencing improves the diagnosis of multiple synchronous lung |
| <u>cancers</u>                                                                                         |
| Manuscript number (if known):                                                                          |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |

| 5  | Payment or honoraria for                        | None              |  |
|----|-------------------------------------------------|-------------------|--|
|    | lectures, presentations,                        |                   |  |
|    | speakers bureaus,                               |                   |  |
|    | manuscript writing or                           |                   |  |
|    | educational events                              |                   |  |
| 6  | Payment for expert                              | None              |  |
|    | testimony                                       |                   |  |
|    |                                                 |                   |  |
| 7  | Support for attending meetings and/or travel    | None              |  |
|    |                                                 |                   |  |
|    |                                                 |                   |  |
| 8  | Patents planned, issued or                      | None              |  |
|    | pending                                         |                   |  |
|    |                                                 |                   |  |
| 9  | Participation on a Data                         | None              |  |
|    | Safety Monitoring Board or                      |                   |  |
|    | Advisory Board                                  |                   |  |
| 10 | Leadership or fiduciary role                    | None              |  |
|    | in other board, society,                        |                   |  |
|    | committee or advocacy                           |                   |  |
|    | group, paid or unpaid                           |                   |  |
| 11 | Stock or stock options                          | None              |  |
|    |                                                 |                   |  |
| 12 | Descint of annique and                          | Nama              |  |
| 12 | Receipt of equipment, materials, drugs, medical | None              |  |
|    | writing, gifts or other                         |                   |  |
|    | services                                        |                   |  |
| 13 | Other financial or non-                         | Novogene Co., Ltd |  |
|    | financial interests                             | ,                 |  |
|    |                                                 |                   |  |
|    |                                                 |                   |  |

| Lin Meng is from Novogene Co., Ltd. |  |
|-------------------------------------|--|
|                                     |  |
|                                     |  |
|                                     |  |
|                                     |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:2023-3-1                                                                                                 |
|---------------------------------------------------------------------------------------------------------------|
| Your Name: Shanshan Shi                                                                                       |
| Manuscript Title: <u>Case report: targeted sequencing improves the diagnosis of multiple synchronous lung</u> |
| <u>cancers</u>                                                                                                |
| Manuscript number (if known):                                                                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |  |  |  |  |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--|--|--|--|--|
|   | Time frame: Since the initial planning of the work                                                                                                                    |                                                                                                          |                                                                                     |  |  |  |  |  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None                                                                                                     |                                                                                     |  |  |  |  |  |
|   | Time frame: past 36 months                                                                                                                                            |                                                                                                          |                                                                                     |  |  |  |  |  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | None                                                                                                     |                                                                                     |  |  |  |  |  |
| 3 | Royalties or licenses                                                                                                                                                 | None                                                                                                     |                                                                                     |  |  |  |  |  |
| 4 | Consulting fees                                                                                                                                                       | None                                                                                                     |                                                                                     |  |  |  |  |  |

| 5  | Payment or honoraria for                              | None              |  |
|----|-------------------------------------------------------|-------------------|--|
|    | lectures, presentations,                              |                   |  |
|    | speakers bureaus,                                     |                   |  |
|    | manuscript writing or                                 |                   |  |
|    | educational events                                    |                   |  |
| 6  | Payment for expert                                    | None              |  |
|    | testimony                                             |                   |  |
| _  |                                                       |                   |  |
| 7  | Support for attending meetings and/or travel          | None              |  |
|    |                                                       |                   |  |
|    |                                                       |                   |  |
| 8  | Patents planned, issued or                            | None              |  |
|    | pending                                               |                   |  |
|    |                                                       |                   |  |
| 9  | Participation on a Data                               | None              |  |
|    | Safety Monitoring Board or                            |                   |  |
|    | Advisory Board                                        |                   |  |
| 10 | Leadership or fiduciary role in other board, society, | None              |  |
|    |                                                       |                   |  |
|    | committee or advocacy                                 |                   |  |
| 11 | group, paid or unpaid                                 | None              |  |
| 11 | Stock or stock options                                | None              |  |
|    |                                                       |                   |  |
| 12 | Receipt of equipment,                                 | None              |  |
|    | materials, drugs, medical                             |                   |  |
|    | writing, gifts or other                               |                   |  |
| 12 | services                                              | N C III           |  |
| 13 | Other financial or non-                               | Novogene Co., Ltd |  |
|    | financial interests                                   |                   |  |
|    |                                                       |                   |  |
|    |                                                       |                   |  |

| Shanshan Shi is from Novogene Co., Ltd. |  |  |  |
|-----------------------------------------|--|--|--|
|                                         |  |  |  |
|                                         |  |  |  |
|                                         |  |  |  |
|                                         |  |  |  |

Please place an "X" next to the following statement to indicate your agreement: